Oxidative stress and DNA damage in obesity-related tumorigenesis

Advances in Experimental Medicine and Biology

Volumn 824, Issue , 2014, Pages 5-17

  Cerdá, Concha ^a   Sánchez, Carlos ^b   Climent, Benjamín ^b   Vázquez, Antonio ^b   Iradi, Antonio ^a   El Amrani, Fátima ^a   Bediaga, Ana ^a   Sáez, Guillermo T ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Cancer; DNA damage; Free radicals; Obesity

Indexed keywords

25 HYDROXYVITAMIN D; 8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL FACTOR; CHOLESTEROL; ISOPROSTANE DERIVATIVE; PHOSPHATIDYLINOSITOL KINASE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN B; SOMATOMEDIN C;

ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CHOLESTEROL BLOOD LEVEL; COLON CANCER; DNA DAMAGE; ENDOMETRIUM CANCER; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONONUCLEAR CELL; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; VITAMIN BLOOD LEVEL; ANIMAL; CELL TRANSFORMATION; COMPLICATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHOLESTEROL; DNA DAMAGE; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84921647846     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-07320-0_2     Document Type: Article

References (97)

1. Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985;311:617-31.
2. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. Oxford, UK: Oxford University Press; 2007.
3. Loft S, Danielson P, Löhr M, Jantzen K, Hemmingsen JG, Roursgaard M, et al. Urinary excretion of 8-oxo- 7,8-dihydroguanine as biomarker of oxidative damage to DNA. Arch Biochem Biophys. 2012; 518:142-50.
4. Barregard L, Møller P, Henriksen T, Mistry V, Koppen G, Rossner Jr P, et al. Human and methodological sources of variability in the measurement of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine. Antioxid Redox Signal. 2013;18:2377-91.
5. Oliva MR, Ripoll F, Muñiz P, Iradi A, Trullenque R, Valls V, et al. Genetic alterations and oxidative metabolism in sporadic colorectal tumors from a Spanish community. Mol Carcinogen. 1997;18:232-43.
6. Oltra AM, Carbonell F, Tormos C, Iradi A, Sáez GT. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Rad Biol Med. 2001;30:1286-92.
7. Sánchez M, Torres JV, Tormos C, Iradi A, Muñiz P, Espinosa O, et al. Impairment of antioxidant enzymes, lipid peroxidation and 8-oxo-2'- deoxyguanosine in advanced epithelial ovarian carcinoma of a spanish community. Cancer Lett. 2006;233:28-35.
8. Collado R, Oliver I, Tormos C, Egea M, Miguel A, Cerdá C, et al. Early ROS-mediated DNA damage and oxidative stress biomarkers in monoclonal B lymphocytosis. Cancer Lett. 2012;317:144-9.
9. Abdilla N, Tormo MC, Fabia MJ, Chaves FJ, Sáez G, Redon J. Impact of the components of metabolic syndrome on oxidative stress and enzymatic antioxidant activity in essential hypertension. J Hum Hypertens. 2007;21:68-75.
10. Martinez-Hervas S, Fandos M, Real JT, Espinosa O, Chaves FJ, Sáez GT, et al. Insulin resistance and oxidative stress in familial combined hyperlipidemia. Atherosclerosis. 2008;199:384-9.
11. Fandos M, Corella D, Guillén M, Portloés O, Carrasco P, Iradi A, et al. Impact of cardiovascular risk factors on oxidative stress and DNA damage in a high risk Mediterranean population. Free Radic Res. 2009;43:1179-89.
12. Mitjavila MT, Fandos M, Salas-Salvadó J, Covas MI, Borrego S, Estruch R, et al. The Mediterranean diet improves the systemic lipid and DNA oxidative damage in metabolic syndrome individuals. A randomized, controlled trial. Clin Nutr. 2013;32:172-8.
13. López-Uriarte P, Nogués R, Saez G, Bulló M, Romeu M, Masana L. Effect of nut consumption on oxidative stress and the endothelial function in metabolic syndrome. Clin Nutr. 2010;29:373-80.
14. Real JT, Martínez-Hervás S, Tormos MC, Domenech E, Pallardó FV, Sáez-Tormo G, et al. Increased oxidative stress levels and normal antioxidant enzyme activity in circulating mononuclear cells from patients of familial hypercholesterolemia. Metabolism. 2010;59:293-8.
15. Kushino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, et al. Misreading of DNA templates containing 8-hydroxy-deoxyguanosine at the modifi ed base and at adjacent residues. Nature. 1987;327:77-9.
16. Shibutani S, Takeshita M, Grollman AP. Insertion of specifi c bases during DNA synthesis past the oxidation- damage base 8-oxo-Dg. Nature. 1991;349: 431-4.
17. Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci U S A. 1999;96: 13300-5.
18. Lichtman MA. Obesity and the risk for a haematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083-101.
19. Robert DL, Dive C, Renehan AF. Biological mechanisms linking obesity and cancer risk. New perspectives. Annu Rev Med. 2010;61:301-6.
20. Lobstein T, Frelut ML. Prevalence of overweight among children in Europe. Obes Rev. 2003;4: 195-200.
21. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev. 2007;29:1-5.
22. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes. 2006;1: 11-25.
23. De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85:660-7.
24. Sánchez-Cruz JJ, Jiménez-Moleón JJ, Fernández- Quesada F, Sánchez MJ. Prevalencia de obesidad infantil y juvenil en España en 2012. Rev Esp Cardiol. 2013;66:371-6.
25. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults. 1999-2008. JAMA. 2010;303:235-41.
26. Demark-Wahnefried W, Platz EA, Ligibel JA, Blair CK, Courneya KS, Meyerhardt JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012;21:1244-59.
27. Haslam D. Obesity: a medical history. Obes Rev. 2007;8 Suppl 1:31-6.
28. Renehan AG, Tyson M, Egger M, Heller F, Swahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
29. Cao Y, Ma J. Body mass index, prostate cancerspecifi c mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4:486-501.
30. Ewertz M, Jensen MB, Grunnarsdottir KA, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29:25-31.
31. Sinicrope FA, Foster NR, Sargent DJ. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16:1884-93.
32. Protani M, Coory M, Marin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627-35.
33. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-38.
34. Wholin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15:556-65.
35. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. Brit Med J. 2007;335:1134-9.
36. Dalling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720-9.
37. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
38. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-91.
39. Hsing AW, Sakoda LC, Chua Jr S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:843-57.
40. Spindler SR. Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. Mech Ageing Dev. 2005;126:960-6.
41. Pallavi R, Giorgio M, Pelicci PG. Insights into the benefi cial effect of caloric/dietary restriction for a healthy and prolonged life. Front Physiol. 2012;3:1-10.
42. Heydari AR, Unnikrishnan A, Lucente LV, Richardson A. Caloric restriction and genomic stability. Nucleic Acids Res. 2007;35:7485-96.
43. McMillan JR, Sattar N, Lean M, McArdle CS. Obesity and cancer. Brit Med J. 2006;333:1109-11.
44. Lagunova Z, Projnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: dose decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res. 2010;54:1127-33.
45. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev. 1994;3:687-95.
46. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6:164-79.
47. Frystyk J. Free insulin-like growth factorsmeasurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14:337-75.
48. Becker S, Lossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009;115:86-96.
49. Pisani P. Hyper-insulinaemia and cancer, metaanalyses of epidemiological studies. Arch Physiol Biochem. 2008;114:63-70.
50. Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk: results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;120:2656-64.
51. Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, Olsen A, et al. Serum C-peptide levels and breast cancer risk: results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2006;119:659-67.
52. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17:328-36.
53. Richart W, Fernandez-Real JM. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance. Obes Res. 2001;9:631-6.
54. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factor and neoplasia. Nat Rev Cancer. 2004;4:505-18.
55. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62:1030-5.
56. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem. 2002;18:15600-6.
57. Canonici A, Steelant W, Rigot V, Khomitch-Baud A, Boutaghou-Cherid H, Bruyneel E. Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer. 2008;122: 572-82.
58. Bray GA. The underlying basis for obesity: relationship to cancer. J Nutr. 2002;132:3451s-5.
59. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153-65.
60. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121:79-90.
61. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2002;293:622-8.
62. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86:s858-66.
63. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.
64. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a casecontrol study in Greece. J Clin Endocrinol Metab. 2003;88:993-7.
65. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699-704.
66. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S, et al. Prostate cancer and adiponectin. Urology. 2005;65:1168-72.
67. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688-94.
68. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic response in human MCF7 breast cancer cells. Boichem Biophys Res Commun. 2006;345:271-8.
69. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin induced antiangiogenic and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101:2476-81.
70. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidativestress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-61.
71. Rindler PM, Plafker SM, Szweda LI, Kinter M. High dietary fat selectively increases catalase expression within cardiac mitochondria. J Biol Chem. 2013;288:1979-90.
72. Dröse S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol. 2012;748:145-69.
73. Diaz-Marco MT, Moscat J. The atypical PKCs in infl ammation: NFkB and beyond. Immunol Rev. 2012;246:154-67.
74. Patel C, Ghanim H, Ravishankar S, Sia CL, Viswanathan P, Mohanty P, et al. Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metabol. 2007;92: 4476-9.
75. Bubici C, Papa S, Dean K, Franzoso G. Mutual crosstalk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological signifi cance. Oncogene. 2006;25:6731-48.
76. Surmi BK, Hasty AH. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vasc Pharmacol. 2010;52:27-36.
77. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236: 313-22.
78. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol. 2009;620: 138-44.
79. Brown LA, Kerr CJ, Whiting P, Finer N, McEneny J, Ashton T. Oxidant stress in healthy normal-weight, overweight, and obese individuals. Obesity. 2009; 17:460-6.
80. Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: strategies fi nalized to improve redox state. Int J Mol Sci. 2013;14:10947-538.
81. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity. 2010;18:1079-84.
82. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapińska E, Majda J, Kustrzeba-Wójcicka I, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity- related infl ammation and oxidative stress. Adv Clin Exp Med. 2013;22:229-36.
83. Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, et al. Impaired paraoxonase- 1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem. 2013;46:1830-6.
84. Canoy D, Wareham N, Welch A, Bingham S, Luben R, Day N, Khaw KT. Plasma ascorbic acid concentrations and fat distribution in 19,068 British men and women in the European prospective investigation into cancer and nutrition Norfolk cohort study. Am J Clin Nutr. 2005;82:1203-9.
85. D'Archivio M, Annuzzi G, Varì R, Filesi C, Giacco R, Scazzocchio B, et al. Predominant role of obesity/ insulin resistance in oxidative development. Eur J Clin Invest. 2012;42:70-8.
86. De Tursi-Ríspoli L, Vázquez-Tarragón A, Vázquez- Prado A, Sáez-Tormo G, Alí-Mahmoud A, Gumbau- Puchol V. Estrés oxidativo; estudio comparativo entre un grupo de población normal y un grupo de población obesa mórbida. Nutr Hosp. 2013;28: 671-5.
87. De Tursi-Ríspoli L, Vázquez-Tarragón A, Vázquez- Prado A, Sáez-Tormo G, Mahmoud AL, Bruna- Esteban M, et al. Relationship of oxidative stress and weight loss achieved in morbid obese patients by means of bariatric surgery using the duodenal switch technique. Nutr Hosp. 2013;28:1085-92.
88. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and infl ammation. Circulation. 2005;111: 1448-54.
89. Il'yasova D, Wang F, Spasojevic I, Base K, D'Agostino Jr RB, Wagenknecht LE. Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity (Silver Spring). 2012;20:1915-21.
90. Kanaya AM, Wassel CL, Stoddard PJ, Harris TB, Cummings SR, Kritchevsky SB, et al. F2-isoprostanes and adiposity in older adults. Obesity (Silver Spring). 2011;19:861-7.
91. Zhang H, Xie C, Spencer HJ, Zuo C, Higuchi M, Ranganathan G, et al. Obesity and hepatosteatosis in mice with enhanced oxidative DNA damage processing in mitochondria. Am J Pathol. 2011;178:1715-27.
92. Sampath H, Vartanian V, Rollins MR, Sakumi K, Nakabeppu Y, Lloyd RS. 8-Oxoguanine DNA glycosilase (OGG1) defi ciency increases susceptibility to obese and metabolic dysfunction. PLoS One. 2012;7:e51697.
93. García-Heredia A, Kensicki E, Mohney RP, Rull A, Triguero I, Marsillach J, et al. Paraoxonase-1 defi ciency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet. A metabolomic approach. J Proteome Res. 2013;12:1946-55.
94. Milić M, Kišan M, Rogulj D, Radman M, Lovrenčić MV, Konjevoda P, et al. Level of primary DNA damage in the early stage of metabolic syndrome. Mutat Res. 2013;758:1-5.
95. Anderson D, Yu TW, Wright J, Ioannides C. An explanation of DNA strand breakage in the comet assay and antioxidant capacity in diabetic patients. Mutat Res. 1998;398:151-61.
96. Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril. 2010;93:2222-31.
97. Dupont C, Faure C, Sermondade N, Boubaya M, Eustache F, Clément P, et al. Obesity leads to higher risk of sperm DNA damage in infertile patients. Asian J Androl. 2013;15:622-5.